Ocrelizumab May Be More Effective for Relapsing-Remitting MS Than Interferon

In any case, infusion reactions with ocrelizumab should be less common than with rituximab, another B-cell depleter used off-label for MS, because ocrelizumab is a more humanized antibody, they concluded.

—M. Alexander Otto